This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
Clinical Lymphoma, Myeloma and Leukemia · 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Nature medicine · 2026
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.
Blood · 2026
Latest funding
- $1,143,676
PIKfyve as a Novel Therapeutic Target for Multiple Myeloma
CIHR · 2026 · Co-investigator
- $990,676
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment
CIHR · 2020 · Principal investigator
- $390,152
Molecular evolution of myeloma from precursor through to relapsed disease
CIHR · 2018 · Principal investigator
96 publications.
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
Mina R, Terpos E, Cani L, Nooka A, Trudel S, Voorhees P, Mian H, Dhakal B, Usmani S, Richter J
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Cohen AD, Richter J, Trudel S, Lesokhin A, Laubach JP, Thomas SK, Harrison SJ, Costa LJ, Spencer A, Fonseca R, Forsberg PA, Berdeja JG, Kaedbey R, Bahlis NJ, Rodriguez-Otero P, Mateos MV, Tyagi T, Samineni D, Liu W, Nakamura R, Choeurng V, Wong C, Cooper J, Krishnan A
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.
Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi S
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.
Sharma R, Pelland AA, Lajkosz K, Masih-Khan E, Vohra HS, Bhella S, Chen CI, Kukreti V, Stewart AK, Trudel S, Yang C, Reece DE, Venner C, Lancman G
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.
Sharma R, Atenafu EG, Masih-Khan E, Vohra H, Bhella S, Chen C, Kukreti V, Lancman G, Prica A, Stewart AK, Tiedemann R, Trudel S, Yang C, Reece D
PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.
Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.
Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodríguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosiñol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC, RedirecTT-1 Investigators Study Group
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.
St Paul M, Hendrikse LD, Ying F, Snow BE, Luo P, Helke S, Smith LK, Hilal A, Abelman DD, Ramamurthy N, Nault H, Wei EN, Gold MJ, Tobin C, Lien SC, Liu Y, Zhou W, Zhang X, Nguyen D, Agbede O, Pedersen S, Eagles J, Saunders ME, Berger T, Wakeham A, Scott DS, Ly D, de Campos CB, Liang G, Zheng C, Wilson WV, Masih-Khan E, White D, McCurdy A, Louzada ML, Kotb R, Chu MP, Parkin S, Reece D, Gul E, Tiedemann R, Pugh TJ, Hirano N, Ohashi PS, Stewart AK, Trudel S, Mak TW
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Mian HS, Visram A, Shih SC-M, Trudel S, Hay AE, LeBlanc R, Sebag M, Kaedbey R, Stakiw J, Sandhu I
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S, DREAMM-8 investigators
PIKfyve as a Novel Therapeutic Target for Multiple Myeloma
Principal investigators: Stewart, Alexander K
Keywords: Autophagy; Immunotherapy; Lysosome; Mouse Models; Myeloma; Pikfyve; Small Molecule
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment
Principal investigators: Pugh, Trevor J; Tiedemann, Rodger; Trudel, Suzanne M
Keywords: Cancer Genomics; Circulating Tumour Dna; Multiple Myeloma; Single Cell Sequencing; Translational Research
Molecular evolution of myeloma from precursor through to relapsed disease
Principal investigators: Pugh, Trevor J; Trudel, Suzanne M
Keywords: Cancer Genomics; Multiple Myeloma; Single Cell Rna-Seq; Tumour Microenvironment
Silencing Stat3 signaling in multiple myeloma: identifying potent small molecule inhibitors of Stat3
Principal investigators: Gunning, Patrick T
Keywords: Anti-Cancer Drugs; Molecular Recognition; Molecular Therapeutics; Multiple Myeloma; Src Homology 2 Domains; Stat3 Protein
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Hira Mian and Alissa Visram: 53 shared papers
- Hira Mian and Arleigh McCurdy: 32 shared papers
- Michael Sebag and Donna Reece: 25 shared papers
- Donna Reece and Arleigh McCurdy: 23 shared papers
- Rodger Tiedemann and Suzanne Trudel: 23 shared papers
- Michael Sebag and Arleigh McCurdy: 21 shared papers
- Donna Reece and Suzanne Trudel: 20 shared papers
- Hira Mian and Donna Reece: 19 shared papers
- Hira Mian and Michael Sebag: 18 shared papers
- Alissa Visram and Arleigh McCurdy: 14 shared papers
- Donna Reece and Rodger Tiedemann: 9 shared papers
- Benjamin Haibe-Kains and Wei Xu: 7 shared papers
- Alissa Visram and Donna Reece: 6 shared papers
- Hira Mian and Suzanne Trudel: 4 shared papers
- Alissa Visram and Suzanne Trudel: 3 shared papers
- Michael Sebag and Suzanne Trudel: 3 shared papers
- Suzanne Trudel and Arleigh McCurdy: 3 shared papers
- Shereen Ezzat and Wei Xu: 2 shared papers
- Shereen Ezzat and Xuan Li: 2 shared papers
- Igor Jurisica and Jason Moffat: 2 shared papers
- David Spaner and Suzanne Trudel: 2 shared papers
- Benjamin Haibe-Kains and Jason Moffat: 2 shared papers
- Donna Reece and Xuan Li: 2 shared papers
- Rodger Tiedemann and Wei Xu: 2 shared papers
- Rodger Tiedemann and Xuan Li: 2 shared papers
- Suzanne Trudel and Xuan Li: 2 shared papers
- Hira Mian and Nizar Bahlis: 1 shared paper
- Michael Sebag and Nizar Bahlis: 1 shared paper
- Shereen Ezzat and Rodger Tiedemann: 1 shared paper
- Shereen Ezzat and Trevor Pugh: 1 shared paper
- Shereen Ezzat and Suzanne Trudel: 1 shared paper
- Nizar Bahlis and Donna Reece: 1 shared paper
- Nizar Bahlis and Suzanne Trudel: 1 shared paper
- Igor Jurisica and Benjamin Haibe-Kains: 1 shared paper
- Igor Jurisica and Suzanne Trudel: 1 shared paper
- Mario Ostrowski and Suzanne Trudel: 1 shared paper
- Benjamin Haibe-Kains and Suzanne Trudel: 1 shared paper
- Jason Moffat and Trevor Pugh: 1 shared paper
- Jason Moffat and Suzanne Trudel: 1 shared paper
- Donna Reece and Naoto Hirano: 1 shared paper
- Donna Reece and Xiao-Yan Wen: 1 shared paper
- Donna Reece and Adam Smith: 1 shared paper
- Rodger Tiedemann and Naoto Hirano: 1 shared paper
- Rodger Tiedemann and Trevor Pugh: 1 shared paper
- Rodger Tiedemann and Christine Cserti-Gazdewich: 1 shared paper
- Wei Xu and Suzanne Trudel: 1 shared paper
- Naoto Hirano and Trevor Pugh: 1 shared paper
- Naoto Hirano and Suzanne Trudel: 1 shared paper
- Trevor Pugh and Suzanne Trudel: 1 shared paper
- James Koropatnick and Suzanne Trudel: 1 shared paper
- Suzanne Trudel and Xiao-Yan Wen: 1 shared paper
- Suzanne Trudel and Christine Cserti-Gazdewich: 1 shared paper
- Suzanne Trudel and Adam Smith: 1 shared paper
- Medicine
- Oncology
- Biostatistics Division
- Department of Laboratory Medicine and Pathobiology
- Department of Medicine
- Cancer and Cell Biology
- Radiation Oncology/Medical Physics
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Rodger Tiedemann
Faculty
23 shared papers, latest 2026
Donna Reece
Faculty
20 shared papers, latest 2026
Hira Mian
Oncology
4 shared papers, latest 2026
Arleigh McCurdy
Department of Medicine
3 shared papers, latest 2026
Alissa Visram
Oncology
3 shared papers, latest 2025
Michael Sebag
Medicine
3 shared papers, latest 2025
Xuan Li
Biostatistics Division
2 shared papers, latest 2022
David Spaner
Cancer and Cell Biology
2 shared papers, latest 2019
Xiao-Yan Wen
Medicine
1 shared papers, latest 2007
Christine Cserti-Gazdewich
Department of Laboratory Medicine and Pathobiology
1 shared papers, latest 2013
Adam Smith
Department of Laboratory Medicine and Pathobiology
1 shared papers, latest 2025
Jason Moffat
Genetics and Genome Biology
1 shared papers, latest 2015
Wei Xu
Biostatistics Division
1 shared papers, latest 2022
Naoto Hirano
Tumor Immunology
1 shared papers, latest 2026
Trevor Pugh
Department of Medical Biophysics
1 shared papers, latest 2026
James Koropatnick
Faculty
1 shared papers, latest 2017
Shereen Ezzat
Medicine
1 shared papers, latest 2007
Nizar Bahlis
Hematology-Oncology
1 shared papers, latest 2024
Igor Jurisica
Rheumatology
1 shared papers, latest 2010
Mario Ostrowski
Medicine
1 shared papers, latest 2016
Benjamin Haibe-Kains
Radiation Oncology/Medical Physics
1 shared papers, latest 2021
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.